Matching articles for "Secuado"
In Brief: An Asenapine Patch (Secuado) for Schizophrenia
A transdermal formulation of the second-generation (atypical) antipsychotic asenapine ( Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the…
Med Lett Drugs Ther. 2021 Jan 11; 63(1615):7-8
A transdermal formulation of the second-generation (atypical) antipsychotic asenapine ( Secuado – Noven) has been approved by the FDA for once-daily treatment of schizophrenia in adults. Asenapine is the first antipsychotic to become available in a transdermal formulation in the US. A twice-daily sublingual tablet formulation of asenapine (Saphris) has been available since 2009.
Lumateperone (Caplyta) for Schizophrenia
The FDA has approved lumateperone ( Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation…
Med Lett Drugs Ther. 2020 Jul 27; 62(1603):113-6
The FDA has approved lumateperone ( Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
